Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 3
---
 sold 708,407 November 2024 Keystone Purchase Shares (as defined below) for aggregate proceeds of $2,623,788 and 1,377,950 November 2024 Keystone Purchase Shares remain available for issuance under the November 2024 Keystone Purchase Agreement. The actual number of shares of our Common Stock issuable will vary depending on the then-current market price of shares of our Common Stock sold to Keystone under the Keystone Purchase Agreements, but will not exceed the number set forth in the preceding sentences unless we file an additional registration statement under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission (the “SEC”). See “ The Committed Equity Financing” for a description of the Keystone Purchase Agreements and “ Selling Securityholder” for additional information regarding Keystone. We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of the shares of our Common Stock by Keystone. Additionally, we will not receive any proceeds from the issuance or sale of the Keystone Commitment Shares. We may receive up to $25.0 million in aggregate gross proceeds from Keystone under the Keystone Purchase Agreements in connection with sales of the shares of our Common Stock to Keystone pursuant to the Keystone Purchase Agreements, including the February 2024 Keystone Purchase Shares and any shares of our Common Stock sold after the date of this prospectus. However, the actual proceeds from Keystone may be less than this amount depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold. As of May 19, 2025, there were 25,578,390 shares of Common Stock outstanding on a fully-diluted basis after giving effect to the conversion of all outstanding shares of our Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, and Series D Preferred Stock (each as defined below) and the exercise of all outstanding Warrants and options (as defined below), of which 24,600,356 shares were held by non-affiliates (without taking into account beneficial ownership or stock exchange limitations). If all of the 2,100,000 shares of our Common Stock offered for resale by Keystone under this prospectus were issued and outstanding as of May 19, 2025 (without taking into account beneficial ownership or stock exchange limitations), such shares would represent approximately 7.6% of total number of shares of our fully-diluted Common Stock outstanding and approximately